geboren 1960

Ausbildung und Qualifikation

Beruflicher Werdegang

Forschungsschwerpunkt

Experimentelle Arbeiten mit Hodgkin-Zellkulturen
Immunologische Forschung über die Biologie von Tumorzellen
Mitwirken bei der Etablierung der autologen Knochenmarkstransplantation 2002 – 2006 in der Medizinische Klinik I

Mitgliedschaften

• Berufsverband der niedergelassenen Hämatologen und Onkologen in Deutschland (BNHO)
• Berufsverband der niedergelassenen Hämatologen und Onkologen Nordrhein (NIONo)
• Hartmannbund

Verzeichnis der wissenschaftlichen Veröffentlichungen

• I Kátay, U Wirnitzer, C von Kalle, E Schell-Frederich, V. Diehl, M Schaadt: L-428 cells derived from Hodgkin’s disease produce E-Rosette inhibiting factor. Blut 1988; 57:Nr. 4
• I Kátay, U Wirnitzer, C von Kalle, E Schell-Frederich, M Schaadt: L-428 cells derived from Hodgkin’s disease produce E-Rosette inhibiting factor. Blood 1990; 76:791-796
• P Dias Wickramanayake, I Kátay, L Mantovani, K Sieg, A Schulz, M Ackermann, V Diehl: Trilinage recovery of refractory severe aplastic anemia (SAA) with recombinant Human Granulocyte-Colony-Stimulating-Factor (G-CSF, Filgrastim), recombinant Human Erythropoetin (EPO) and Cyclosporin A (CSA). International Cytokine Congress Munich, 1993
• P Dias Wickramanayake, I Kátay, L Mantovani, K Sieg, A Schulz, M Ackermann, V Diehl: Successfull treatment of refractory severe aplastic anemia (SAA) with recombinant Human Granulocyte-Colony-Stimulating-Factor (G-CSF, Filgrastim), recombinant Human Erythropoetin (EPO) and Cyclosporin A (CSA). Blood 1993; ASH Abstract
• HT Steinmetz, I Kátay, A Glasmacher, P Staib, V Diehl, P Dias Wickramanayake: Phase II trial of Idarubicin, Fludarabine, ARA-C and Filgrastim (G-CSF) (IDA-FLAG) for treatment of poor prognosis Acute Myeloid Leucemia (AML). Blood 1995; ASH Abstract
• A Josting, U Rüffer, I Kátay, A Schulz, C Scheid, V Diehl, P Dias Wickramanayake: Dexa-BEAM chemotherapy in relapsed or resistant Non-Hodgkin-Lymphoma. Onkologie 1995; 18:246-250
• P Dias Wickramanayake, C Scheid, A Josting, I Kátay, A Schulz, V Diehl: Use of Granylocyte Colony-Stimulating Factor (Filgrastim) in the treatment of non-zytotoxic drug-induced agranulozytosis. Eur J Med Res 1995; 1: 153-156
• P Dias Wickramanayake, I Kátay, A Josting, A Schulz, C Scheid, V Diehl: Risk assessment in myelodysplastic syndromes (MDS). A cytological and clinical study of 49 patients. Strahlentherapie 1996
• P Dias Wickramanayake, I Kátay, A Josting, V Diehl: Adjuvante systemische Therapie des Mammakarzinoms. Med Klinik 1996
• I Kátay, A Josting, S Winter, C Scheid, H Tesch, A Schulz, K Sieg, T Steinmetz, V Diehl, P Dias Wickramanayake: Treatment of patients with relapsed and resistant Hodgkin’s Lymphoma (HD) and Non-Hodgkin-Lymphoma (NHL) using Dexamethasone, BCNU, Melphalan, VP-16 and ARA-C (Dexa-BEAM) with autologous bone marrow or peripheral blood stem cell transplantation (PBSC). EHA Abstract 1996
• R Hinrichs, C Scheid, S Winter, I Kátay, A Schulz, A Josting, V Diehl, P Dias Wickramanayake: Changes in T-cell subpopulations and NK function early after peripheral stem cell transplantation. EHA Abstract 1996
• A Schulz, P Engeling, G Kochanek, C Scheid, A Josting, I Kátay, V Diehl, P Dias Wickramanayake: Induction of apoptosis with 9-ß-D-Arabinosil-2-Fluoroadenine, Daunorubicine, 2-Chlorodezoxy-Adenosine, 1-ß-D-Arabino-Fluranosil-Cytosine in freshly isolated leukaemia cells in relation to clinical response to chemotherapy. EHA Abstract 1996
• A Schulz, P Engeling, G Kochanek, C Scheid, A Josting, I Kátay, V Diehl, P Dias Wickramanayake: P-Glucoprotein and CD34 expression in Acute Myeloid Leukemia (AML): Assessment of clinical significance. EHA Abstract 1996